-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that CSPC Ouyi Pharmaceutical's parecoxib sodium for injection has entered the administrative examination and approval stage with imitation of category 4 products
.
According to data from Meinenet, in 2020, the sales of parecoxib injections in China's public medical institutions will exceed 2 billion yuan, and 2021H1 will drop 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
.
According to data from Meinenet, in 2020, the sales of parecoxib injections in China's public medical institutions will exceed 2 billion yuan, and 2021H1 will drop 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
Parecoxib sodium belongs to non-steroidal anti-inflammatory drugs (NSAIDs).
It is clinically used for surgical pain control.
It has been recommended by authoritative clinical guidelines at home and abroad.
It is widely used in orthopedics, general surgery, hepatobiliary surgery and other departments for postoperative pain Short-term treatment
.
It is clinically used for surgical pain control.
It has been recommended by authoritative clinical guidelines at home and abroad.
It is widely used in orthopedics, general surgery, hepatobiliary surgery and other departments for postoperative pain Short-term treatment
.
Sales of parecoxib sodium for terminal injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
The original research company of Parecoxib Sodium for Injection was Pharmacia (acquired by Pfizer), which was listed in China in 2008
.
According to data from Meinenet, in 2020, the sales of terminal parecoxib injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 2 billion yuan, and 2021H1 fell 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
This product ranks first in the TOP10 anti-inflammatory drugs and anti-rheumatic drugs
.
.
According to data from Meinenet, in 2020, the sales of terminal parecoxib injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 2 billion yuan, and 2021H1 fell 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
This product ranks first in the TOP10 anti-inflammatory drugs and anti-rheumatic drugs
.
It is worth noting that parecoxib sodium for injection is the fourth batch of centralized procurement.
Qilu Pharmaceuticals, Hunan Kelun Pharmaceuticals, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceuticals and other 10 companies won the bids.
With the implementation of centralized procurements , Pfizer's market share will further decline
.
Qilu Pharmaceuticals, Hunan Kelun Pharmaceuticals, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceuticals and other 10 companies won the bids.
With the implementation of centralized procurements , Pfizer's market share will further decline
.
There are more than 30 manufacturers of parecoxib sodium for injection, of which more than 20 have been reviewed
.
At present, supplementary applications for consistency evaluation of Zhejiang Jinhua Kangenba Biopharmaceuticals, Hunan Sailong Pharmaceuticals, and Chengdu Tongde Pharmaceuticals are under review and approval
.
In addition, 10 companies including Shandong New Times Pharmaceutical, Heilongjiang Zhenbaodao Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical are under review and approval for imitation 4 types of production, and CSPC Ouyi Pharmaceutical is under review and approval for imitation 4 types of production.
Stage, after approval, it will be regarded as over-evaluation
.
.
At present, supplementary applications for consistency evaluation of Zhejiang Jinhua Kangenba Biopharmaceuticals, Hunan Sailong Pharmaceuticals, and Chengdu Tongde Pharmaceuticals are under review and approval
.
In addition, 10 companies including Shandong New Times Pharmaceutical, Heilongjiang Zhenbaodao Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical are under review and approval for imitation 4 types of production, and CSPC Ouyi Pharmaceutical is under review and approval for imitation 4 types of production.
Stage, after approval, it will be regarded as over-evaluation
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, CSPC has 15 products approved
.
Among them, amphotericin B cholesterol sulfate complex for injection and nintedanib ethanesulfonate soft capsules are the first imitations; from the perspective of the treatment field, anti- tumor and immunomodulators and digestive system and metabolic drugs are the most numerous, each with 4 a
.
.
Among them, amphotericin B cholesterol sulfate complex for injection and nintedanib ethanesulfonate soft capsules are the first imitations; from the perspective of the treatment field, anti- tumor and immunomodulators and digestive system and metabolic drugs are the most numerous, each with 4 a
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, the official website of the State Food and Drug Administration showed that CSPC Ouyi Pharmaceutical's parecoxib sodium for injection has entered the administrative examination and approval stage with imitation of category 4 products
.
According to data from Meinenet, in 2020, the sales of parecoxib injections in China's public medical institutions will exceed 2 billion yuan, and 2021H1 will drop 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
.
According to data from Meinenet, in 2020, the sales of parecoxib injections in China's public medical institutions will exceed 2 billion yuan, and 2021H1 will drop 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
Parecoxib sodium belongs to non-steroidal anti-inflammatory drugs (NSAIDs).
It is clinically used for surgical pain control.
It has been recommended by authoritative clinical guidelines at home and abroad.
It is widely used in orthopedics, general surgery, hepatobiliary surgery and other departments for postoperative pain Short-term treatment
.
It is clinically used for surgical pain control.
It has been recommended by authoritative clinical guidelines at home and abroad.
It is widely used in orthopedics, general surgery, hepatobiliary surgery and other departments for postoperative pain Short-term treatment
.
Sales of parecoxib sodium for terminal injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
The original research company of Parecoxib Sodium for Injection was Pharmacia (acquired by Pfizer), which was listed in China in 2008
.
According to data from Meinenet, in 2020, the sales of terminal parecoxib injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 2 billion yuan, and 2021H1 fell 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
This product ranks first in the TOP10 anti-inflammatory drugs and anti-rheumatic drugs
.
.
According to data from Meinenet, in 2020, the sales of terminal parecoxib injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 2 billion yuan, and 2021H1 fell 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
This product ranks first in the TOP10 anti-inflammatory drugs and anti-rheumatic drugs
.
It is worth noting that parecoxib sodium for injection is the fourth batch of centralized procurement.
Qilu Pharmaceuticals, Hunan Kelun Pharmaceuticals, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceuticals and other 10 companies won the bids.
With the implementation of centralized procurements , Pfizer's market share will further decline
.
Qilu Pharmaceuticals, Hunan Kelun Pharmaceuticals, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceuticals and other 10 companies won the bids.
With the implementation of centralized procurements , Pfizer's market share will further decline
.
There are more than 30 manufacturers of parecoxib sodium for injection, of which more than 20 have been reviewed
.
At present, supplementary applications for consistency evaluation of Zhejiang Jinhua Kangenba Biopharmaceuticals, Hunan Sailong Pharmaceuticals, and Chengdu Tongde Pharmaceuticals are under review and approval
.
In addition, 10 companies including Shandong New Times Pharmaceutical, Heilongjiang Zhenbaodao Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical are under review and approval for imitation 4 types of production, and CSPC Ouyi Pharmaceutical is under review and approval for imitation 4 types of production.
Stage, after approval, it will be regarded as over-evaluation
.
.
At present, supplementary applications for consistency evaluation of Zhejiang Jinhua Kangenba Biopharmaceuticals, Hunan Sailong Pharmaceuticals, and Chengdu Tongde Pharmaceuticals are under review and approval
.
In addition, 10 companies including Shandong New Times Pharmaceutical, Heilongjiang Zhenbaodao Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical are under review and approval for imitation 4 types of production, and CSPC Ouyi Pharmaceutical is under review and approval for imitation 4 types of production.
Stage, after approval, it will be regarded as over-evaluation
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, CSPC has 15 products approved
.
Among them, amphotericin B cholesterol sulfate complex for injection and nintedanib ethanesulfonate soft capsules are the first imitations; from the perspective of the treatment field, anti- tumor and immunomodulators and digestive system and metabolic drugs are the most numerous, each with 4 a
.
.
Among them, amphotericin B cholesterol sulfate complex for injection and nintedanib ethanesulfonate soft capsules are the first imitations; from the perspective of the treatment field, anti- tumor and immunomodulators and digestive system and metabolic drugs are the most numerous, each with 4 a
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, the official website of the State Food and Drug Administration showed that CSPC Ouyi Pharmaceutical's parecoxib sodium for injection has entered the administrative examination and approval stage with imitation of category 4 products
.
According to data from Meinenet, in 2020, the sales of parecoxib injections in China's public medical institutions will exceed 2 billion yuan, and 2021H1 will drop 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
.
According to data from Meinenet, in 2020, the sales of parecoxib injections in China's public medical institutions will exceed 2 billion yuan, and 2021H1 will drop 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
Parecoxib sodium belongs to non-steroidal anti-inflammatory drugs (NSAIDs).
It is clinically used for surgical pain control.
It has been recommended by authoritative clinical guidelines at home and abroad.
It is widely used in orthopedics, general surgery, hepatobiliary surgery and other departments for postoperative pain Short-term treatment
.
It is clinically used for surgical pain control.
It has been recommended by authoritative clinical guidelines at home and abroad.
It is widely used in orthopedics, general surgery, hepatobiliary surgery and other departments for postoperative pain Short-term treatment
.
Sales of parecoxib sodium for terminal injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
The original research company of Parecoxib Sodium for Injection was Pharmacia (acquired by Pfizer), which was listed in China in 2008
.
According to data from Meinenet, in 2020, the sales of terminal parecoxib injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 2 billion yuan, and 2021H1 fell 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
This product ranks first in the TOP10 anti-inflammatory drugs and anti-rheumatic drugs
.
Hospital hospital hospital.
According to data from Meinenet, in 2020, the sales of terminal parecoxib injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 2 billion yuan, and 2021H1 fell 8.
18% year-on-year.
Among them, Pfizer has the largest market share
.
This product ranks first in the TOP10 anti-inflammatory drugs and anti-rheumatic drugs
.
It is worth noting that parecoxib sodium for injection is the fourth batch of centralized procurement.
Qilu Pharmaceuticals, Hunan Kelun Pharmaceuticals, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceuticals and other 10 companies won the bids.
With the implementation of centralized procurements , Pfizer's market share will further decline
.
Enterprise business enterpriseQilu Pharmaceuticals, Hunan Kelun Pharmaceuticals, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceuticals and other 10 companies won the bids.
With the implementation of centralized procurements , Pfizer's market share will further decline
.
There are more than 30 manufacturers of parecoxib sodium for injection, of which more than 20 have been reviewed
.
At present, supplementary applications for consistency evaluation of Zhejiang Jinhua Kangenba Biopharmaceuticals, Hunan Sailong Pharmaceuticals, and Chengdu Tongde Pharmaceuticals are under review and approval
.
In addition, 10 companies including Shandong New Times Pharmaceutical, Heilongjiang Zhenbaodao Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical are under review and approval for imitation 4 types of production, and CSPC Ouyi Pharmaceutical is under review and approval for imitation 4 types of production.
Stage, after approval, it will be regarded as over-evaluation
.
.
At present, supplementary applications for consistency evaluation of Zhejiang Jinhua Kangenba Biopharmaceuticals, Hunan Sailong Pharmaceuticals, and Chengdu Tongde Pharmaceuticals are under review and approval
.
In addition, 10 companies including Shandong New Times Pharmaceutical, Heilongjiang Zhenbaodao Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical are under review and approval for imitation 4 types of production, and CSPC Ouyi Pharmaceutical is under review and approval for imitation 4 types of production.
Stage, after approval, it will be regarded as over-evaluation
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, CSPC has 15 products approved
.
Among them, amphotericin B cholesterol sulfate complex for injection and nintedanib ethanesulfonate soft capsules are the first imitations; from the perspective of the treatment field, anti- tumor and immunomodulators and digestive system and metabolic drugs are the most numerous, each with 4 a
.
Amphoteric amphoteric amphoteric tumors tumors tumors.
Among them, amphotericin B cholesterol sulfate complex for injection and nintedanib ethanesulfonate soft capsules are the first imitations; from the perspective of the treatment field, anti- tumor and immunomodulators and digestive system and metabolic drugs are the most numerous, each with 4 a
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
Source: official website of the State Food and Drug Administration, Mi Nei. com database
com database
